Noxopharm Limited (ASX:NOX) Announces Positive Sofra™ Data from BioRay Collaboration
Collaboration with BioRay Pharmaceutical
Noxopharm Limited has entered a Material Transfer Agreement with BioRay Pharmaceutical, a leading player in China’s biopharmaceutical sector. BioRay is exploring the versatility and commercial potential of Noxopharm’s Sofra™ assets.
Positive Data and Platform Validation
BioRay’s testing confirmed targeted anti-inflammatory activity of Sofra™ oligonucleotides. The conjugated drugs significantly enhanced BioRay’s antibodies in reducing inflammation markers, externally validating Sofra™ data robustness and demonstrating its broad potential.
Executive Comments
BioRay Head of R&D Dr Gang Chen said: “We are delighted to announce our strategic collaboration with Noxopharm and are very impressed with the efficacy of the asset supplied to us. The encouraging research findings not only confirm the cutting-edge value of the Sofra platform, but also highlight the tremendous potential of our joint development efforts.”
CEO Dr Gisela Mautner said: “We would like to express our thanks to BioRay for committing time and resources to examine our highly innovative assets, which can support companies in enhancing the performance of their drugs. We are delighted that our Sofra drugs have shown strong anti-inflammatory results in studies by an independent company, therefore validating the robustness of our data.”
“Our MTA with BioRay is just one of several with companies around the world, and we are pleased that we are off to such a good start with these results. Sofra technology is versatile and has numerous use cases, and in the months ahead we aim to continue demonstrating why this technology is so promising.”
Motley Fool contributor Kiarra Jackson has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.
This article was generated using GPT-4o mini, a Large Language Model (LLM), to generate summaries of investing news. While AI is generating the content, we know better than to blindly trust our future robot overlords, and every article is edited and fact-checked by an editor holding the appropriate credentials. The Motley Fool Australia stands behind the work of our editorial team and takes ultimate responsibility for the content of everything published by The Capital Club.
